Trial Profile
First-line afatinib in patients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutations; non-randomized phase II trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.